{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:23:29Z","timestamp":1782264209544,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"20","license":[{"start":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T00:00:00Z","timestamp":1533686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012319","name":"Max Planck Institute for Dynamics of Complex Technical Systems","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00253-018-9275-z","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T05:29:47Z","timestamp":1533706187000},"page":"8725-8737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Process intensification of EB66\u00ae cell cultivations leads to high-yield yellow fever and Zika virus production"],"prefix":"10.1007","volume":"102","author":[{"given":"Alexander","family":"Nikolay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"L\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Genzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,8]]},"reference":[{"issue":"5","key":"9275_CR1","first-page":"419","volume":"64","author":"SW Brown","year":"2010","unstructured":"Brown SW, Mehtali M (2010) The avian EB66\u00ae cell line, application to vaccines, and therapeutic protein production. PDA J Pharm Sci Technol 64(5):419\u2013425","journal-title":"PDA J Pharm Sci Technol"},{"issue":"10","key":"9275_CR2","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3201\/eid2210.160875","volume":"22","author":"CH Calisher","year":"2016","unstructured":"Calisher CH, Woodall JP (2016) Yellow fever-more a policy and planning problem than a biological one. Emerg Infect Dis 22(10):1859\u20131860. \n                    https:\/\/doi.org\/10.3201\/eid2210.160875","journal-title":"Emerg Infect Dis"},{"issue":"35","key":"9275_CR3","doi-asserted-by":"publisher","first-page":"14802","DOI":"10.1073\/pnas.0905912106","volume":"106","author":"C Chu","year":"2009","unstructured":"Chu C, Lugovtsev V, Golding H, Betenbaugh M, Shiloach J (2009) Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc Natl Acad Sci U S A 106(35):14802\u201314807. \n                    https:\/\/doi.org\/10.1073\/pnas.0905912106","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9275_CR4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/btpr.1704","volume":"29","author":"M-F Clincke","year":"2013","unstructured":"Clincke M-F, M\u00f6lleryd C, Zhang Y, Lindskog E, Walsh K, Chotteau V (2013) Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor\u2122. Part I Effect of the Cell Density on the Process. Biotechnol Prog 29(3):754\u2013767. \n                    https:\/\/doi.org\/10.1002\/btpr.1704","journal-title":"Biotechnol Prog"},{"key":"9275_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nri.2017.132","volume":"18","author":"MS Diamond","year":"2017","unstructured":"Diamond MS, Coyne CB (2017) Vaccines in 2017: closing in on a Zika virus vaccine. Nat Rev Immunol 18:89\u201390. \n                    https:\/\/doi.org\/10.1038\/nri.2017.132","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"9275_CR6","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1128\/jcm.01799-12","volume":"50","author":"C Domingo","year":"2012","unstructured":"Domingo C, Patel P, Yillah J, Weidmann M, Mendez JA, Nakoune ER, Niedrig M (2012) Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. JCM 50(12):4054\u20134060. \n                    https:\/\/doi.org\/10.1128\/jcm.01799-12","journal-title":"JCM"},{"issue":"1","key":"9275_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1023\/A:1026192228471","volume":"42","author":"JE Dowd","year":"2003","unstructured":"Dowd JE, Jubb A, Kwok KE, Piret JM (2003) Optimization and control of perfusion cultures using a viable cell probe and cell specific perfusion rates. Cytotechnology 42(1):35\u201345. \n                    https:\/\/doi.org\/10.1023\/A:1026192228471","journal-title":"Cytotechnology"},{"issue":"21","key":"9275_CR8","doi-asserted-by":"publisher","first-page":"8999","DOI":"10.1007\/s00253-014-5933-y","volume":"98","author":"T Frensing","year":"2014","unstructured":"Frensing T, Pflugmacher A, Bachmann M, Peschel B, Reichl U (2014) Impact of defective interfering particles on virus replication and antiviral host response in cell culture-based influenza vaccine production. Appl Microbiol Biotechnol 98(21):8999\u20139008. \n                    https:\/\/doi.org\/10.1007\/s00253-014-5933-y","journal-title":"Appl Microbiol Biotechnol"},{"issue":"9","key":"9275_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1586\/14760584.2015.1067144","volume":"14","author":"LE Gallo-Ramirez","year":"2015","unstructured":"Gallo-Ramirez LE, Nikolay A, Genzel Y, Reichl U (2015) Bioreactor concepts for cell culture-based viral vaccine production. Expert Rev Vaccines 14(9):1181\u20131195. \n                    https:\/\/doi.org\/10.1586\/14760584.2015.1067144","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"9275_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1586\/erv.09.128","volume":"8","author":"Y Genzel","year":"2009","unstructured":"Genzel Y, Reichl U (2009) Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 8(12):1681\u20131692. \n                    https:\/\/doi.org\/10.1586\/erv.09.128","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"9275_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00253-012-4238-2","volume":"97","author":"Y Genzel","year":"2013","unstructured":"Genzel Y, Behrendt I, R\u00f6dig J, Rapp E, Kueppers C, Kochanek S, Schiedner G, Reichl U (2013) CAP, a new human suspension cell line for influenza virus production. Appl Microbiol Biotechnol 97(1):111\u2013122. \n                    https:\/\/doi.org\/10.1007\/s00253-012-4238-2","journal-title":"Appl Microbiol Biotechnol"},{"issue":"24","key":"9275_CR12","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.vaccine.2014.02.016","volume":"32","author":"Y Genzel","year":"2014","unstructured":"Genzel Y, Vogel T, Buck J, Behrendt I, Ramirez DV, Schiedner G, Jordan I, Reichl U (2014) High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza a virus production using suspension cells. Vaccine 32(24):2770\u20132781. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.016","journal-title":"Vaccine"},{"issue":"3","key":"9275_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0141-0229(87)90075-5","volume":"9","author":"CM Harris","year":"1987","unstructured":"Harris CM, Todd RW, Bungard SJ, Lovitt RW, Morris JG, Kell DB (1987) Dielectric permittivity of microbial suspensions at radio frequencies: a novel method for the real-time estimation of microbial biomass. Enzym Microb Technol 9(3):181\u2013186. \n                    https:\/\/doi.org\/10.1016\/0141-0229(87)90075-5","journal-title":"Enzym Microb Technol"},{"issue":"5","key":"9275_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.vaccine.2008.11.066","volume":"27","author":"I Jordan","year":"2009","unstructured":"Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V (2009) An avian cell line designed for production of highly attenuated viruses. Vaccine 27(5):748\u2013756. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2008.11.066","journal-title":"Vaccine"},{"key":"9275_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/10_016","volume":"101","author":"K Konstantinov","year":"2006","unstructured":"Konstantinov K, Goudar C, Ng M, Meneses R, Thrift J, Chuppa S, Matanguihan C, Michaels J, Naveh D (2006) The \"push-to-low\" approach for optimization of high-density perfusion cultures of animal cells. Adv Biochem Engin\/Biotechnol 101:75\u201398","journal-title":"Adv Biochem Engin\/Biotechnol"},{"issue":"8","key":"9275_CR16","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3201\/eid1408.080287","volume":"14","author":"RS Lanciotti","year":"2008","unstructured":"Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield SM, Duffy MR (2008) Genetic and serologic properties of Zika virus associated with an epidemic, yap state, Micronesia, 2007. Emerg Infect Dis 14(8):1232\u20131239. \n                    https:\/\/doi.org\/10.3201\/eid1408.080287","journal-title":"Emerg Infect Dis"},{"issue":"48","key":"9275_CR17","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1016\/j.vaccine.2016.10.043","volume":"34","author":"A Leon","year":"2016","unstructured":"Leon A, David AL, Madeline B, Guianvarch L, Dureau E, Champion-Arnaud P, Hebben M, Huss T, Chatrenet B, Schwamborn K (2016) The EB66\u00ae cell line as a valuable cell substrate for MVA-based vaccines production. Vaccine 34(48):5878\u20135885. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.043","journal-title":"Vaccine"},{"issue":"1","key":"9275_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41467-018-02975-w","volume":"9","author":"X-F Li","year":"2018","unstructured":"Li X-F, Dong H-L, Wang H-J, Huang X-Y, Qiu Y-F, Ji X, Ye Q, Li C, Liu Y, Deng Y-Q, Jiang T, Cheng G, Zhang F-C, Davidson AD, Song Y-J, Shi P-Y, Qin C-F (2018) Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. Nat Commun 9(1):673. \n                    https:\/\/doi.org\/10.1038\/s41467-018-02975-w","journal-title":"Nat Commun"},{"issue":"36","key":"9275_CR19","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1016\/j.vaccine.2009.05.083","volume":"27","author":"V Lohr","year":"2009","unstructured":"Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U (2009) New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 27(36):4975\u20134982. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2009.05.083","journal-title":"Vaccine"},{"issue":"22","key":"9275_CR20","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","volume":"28","author":"TP Monath","year":"2010","unstructured":"Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW (2010) Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28(22):3827\u20133840. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2010.03.023","journal-title":"Vaccine"},{"issue":"10028","key":"9275_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0140-6736(16)30195-7","volume":"387","author":"TP Monath","year":"2016","unstructured":"Monath TP, Woodall JP, Gubler DJ, Yuill TM, Mackenzie JS, Martins RM, Reiter P, Heymann DL (2016) Yellow fever vaccine supply: a possible solution. Lancet 387(10028):1599\u20131600. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)30195-7","journal-title":"Lancet"},{"key":"9275_CR22","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.vaccine.2017.03.018","volume":"36","author":"A Nikolay","year":"2017","unstructured":"Nikolay A, Castilho LR, Reichl U, Genzel Y (2017) Propagation of Brazilian Zika virus strains in static and suspension cultures using Vero and BHK cells. Vaccine 36:3140\u20133145. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.018","journal-title":"Vaccine"},{"issue":"17\u201319","key":"9275_CR23","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1016\/S0264-410X(00)00508-9","volume":"19","author":"MG Pau","year":"2001","unstructured":"Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F (2001) The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19(17\u201319):2716\u20132721","journal-title":"Vaccine"},{"key":"9275_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1472-6750-11-84","volume":"11","author":"E Petiot","year":"2011","unstructured":"Petiot E, Jacob D, Lanthier S, Lohr V, Ansorge S, Kamen AA (2011) Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnol 11:84\u201384. \n                    https:\/\/doi.org\/10.1186\/1472-6750-11-84","journal-title":"BMC Biotechnol"},{"key":"9275_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jbiotec.2016.11.010","volume":"242","author":"E Petiot","year":"2017","unstructured":"Petiot E, Ansorge S, Rosa-Calatrava M, Kamen A (2017) Critical phases of viral production processes monitored by capacitance. J Biotechnol 242:19\u201329. \n                    https:\/\/doi.org\/10.1016\/j.jbiotec.2016.11.010","journal-title":"J Biotechnol"},{"issue":"5","key":"9275_CR26","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/bit.24808","volume":"110","author":"G Seth","year":"2013","unstructured":"Seth G, Hamilton RW, Stapp TR, Zheng L, Meier A, Petty K, Leung S, Chary S (2013) Development of a new bioprocess scheme using frozen seed train intermediates to initiate CHO cell culture manufacturing campaigns. Biotechnol Bioeng 110(5):1376\u20131385. \n                    https:\/\/doi.org\/10.1002\/bit.24808","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"9275_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41467-017-00737-8","volume":"8","author":"C Shan","year":"2017","unstructured":"Shan C, Muruato AE, Jagger BW, Richner J, Nunes BTD, Medeiros DBA, Xie X, Nunes JGC, Morabito KM, Kong WP, Pierson TC, Barrett AD, Weaver SC, Rossi SL, Vasconcelos PFC, Graham BS, Diamond MS, Shi PY (2017) A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nat Commun 8(1):676. \n                    https:\/\/doi.org\/10.1038\/s41467-017-00737-8","journal-title":"Nat Commun"},{"issue":"6","key":"9275_CR28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1084\/jem.65.6.787","volume":"65","author":"M Theiler","year":"1937","unstructured":"Theiler M, Smith HH (1937) The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65(6):787\u2013800","journal-title":"J Exp Med"},{"issue":"8","key":"9275_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1089\/vbz.2016.2031","volume":"16","author":"PF Vasconcelos","year":"2016","unstructured":"Vasconcelos PF, Monath TP (2016) Yellow fever remains a potential threat to public health. Vector Borne Zoonotic Dis 16(8):566\u2013567. \n                    https:\/\/doi.org\/10.1089\/vbz.2016.2031","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"22","key":"9275_CR30","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.vaccine.2017.10.112","volume":"36","author":"Daniel V\u00e1zquez-Ram\u00edrez","year":"2018","unstructured":"V\u00e1zquez-Ram\u00edrez D, Genzel Y, Jordan I, Sandig V, Reichl U (2018) High-cell-density cultivations to increase MVA virus production. Vaccine InPress doi:\n                    https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.112\n                    \n                  , 36, 3124, 3133","journal-title":"Vaccine"},{"key":"9275_CR31","volume-title":"Global strategy to eliminate yellow fever epidemics (EYE)","author":"WHO","year":"2016","unstructured":"WHO (2016a) Global strategy to eliminate yellow fever epidemics (EYE). World Health Organization, Geneva"},{"key":"9275_CR32","unstructured":"WHO (2016b) Yellow fever global vaccine stockpile in emergencies. \n                    http:\/\/www.who.int\/features\/2016\/yellow-fever-vaccine-stockpile\/en\/\n                    \n                   Accessed 21\/02\/2018"},{"key":"9275_CR33","doi-asserted-by":"publisher","unstructured":"Wilder-Smith A, Leong WY (2017) Importation of yellow fever into China: assessing travel patterns. J Travel Med 24(4). \n                    https:\/\/doi.org\/10.1093\/jtm\/tax008","DOI":"10.1093\/jtm\/tax008"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00253-018-9275-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-018-9275-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-018-9275-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T19:18:27Z","timestamp":1565205507000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00253-018-9275-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,8]]},"references-count":33,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["9275"],"URL":"https:\/\/doi.org\/10.1007\/s00253-018-9275-z","relation":{},"ISSN":["0175-7598","1432-0614"],"issn-type":[{"value":"0175-7598","type":"print"},{"value":"1432-0614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,8]]},"assertion":[{"value":"3 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest. AL and KS are employees of Valneva SE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}